Rilvegostomig - Astrazeneca
Alternative Names: AZD-2936Latest Information Update: 07 Aug 2024
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Daiichi Sankyo Company; Presage Biosciences
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Biliary cancer; Non-small cell lung cancer
- Phase II Adenocarcinoma; Gastric cancer; Liver cancer; Solid tumours
- Phase 0 Squamous cell cancer
Most Recent Events
- 05 Aug 2024 Phase-I development for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) is still ongoing in Belgium, France, Japan, Poland, Spain, Taiwan, Turkey and USA (IV), (NCT04612751)
- 05 Aug 2024 AstraZeneca announces intention to submit regulatory application for Biliary cancer (Adjunctive therapy) in 2025 or later
- 21 Jun 2024 AstraZeneca plans phase-III DESTINY-BTC01 trial for Biliary cancer (Combination therapy, Unresectable/Inoperable, Late-stage disease, Metastatic disease, First-line therapy) in Austria, Belgium, Brazil, Canada, Germany, Japan, South Korea, Netherlands and Taiwan(IV) in June 2024 , (NCT06467357)